An­a­lysts write off Di­men­sion’s lead pro­gram af­ter see­ing weak da­ta on he­mo­phil­ia B, shares plunge

Shares of Di­men­sion Ther­a­peu­tics $DMTX were pum­meled on Tues­day, af­ter the biotech post­ed sub­par Fac­tor IX scores on its gene ther­a­py pro­gram for he­mo­phil­ia B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER